The Pharma Industry witnessed another eventful week, with developments across regulation, innovation, manufacturing, and public health.
1.jpg)
The government sets new regulatory rules on drug launches, that relieves the hurdles for Indian manufacturers in obtaining regulatory approvals for supply delays. This in turn, aims to improve the quick market entry of drugs and improve sales
India may need to rethink its India drug rules before making changes that could impact the country's position as a global leader in affordable medicines.
Good health is not built through quick fixes. It grows from small Health Habits that people follow every day. Most doctors say the basics beat any supplement or diet trend.
A monthly recap on major events in indian pharmacuetical industry, which saw numerous policy reforms, innovation, drug approvals, and disease control methods
India has earned global recognition for its India pharma industry, but the next phase of growth could depend on a major shift.
Aarogya Setu 2.0 is no longer just a COVID-19 app. The Centre has launched a revamped version of the platform with several new features that bring PM-JAY Wallet, Digital Health Records, and other healthcare services under one roof.
The global diabetes clinical trials market is on a steady upward trajectory, projected to grow from USD 5.45 billion in 2026 to USD 10.02 billion by 2034, at a CAGR of 7.9 percent, according to a comprehensive new industry analysis.
.jpg)
A new rule comes into line for expanding the residual shell life of imported drugs in India,amid the wastage of medicines and the capital loss in operation and supply chain management
In an exclusive interview with Thiruamuthan, Assistant Editor at India Pharma Outlook, Nilesh Pendse, Director – Vaccines, Pfizer India, discusses the evolving narrative around adult immunization in India. He highlights the importance of awareness, p
, CDSCO.jpg)